董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
James E. Davis Chairman, Chief Executive Officer and President 62 1440.49万美元 11.40 2025-05-15
Wright L. Lassiter III Independent Director 61 32.77万美元 未持股 2025-05-15
Luiz A. Diaz, Jr. Independent Director 54 32.50万美元 0.05 2025-05-15
Gary M. Pfeiffer Independent Director 75 36.07万美元 未持股 2025-05-15
Timothy M. Ring Lead Independent Director 67 37.80万美元 未持股 2025-05-15
Denise M. Morrison Independent Director 71 34.47万美元 0.42 2025-05-15
Robert B. Carter Independent Director 65 28.01万美元 未持股 2025-05-15
Vicky B. Gregg Independent Director 70 34.47万美元 1.40 2025-05-15
Timothy L. Main Independent Director 68 34.27万美元 2.23 2025-05-15
Tracey C. Doi Independent Director 64 32.77万美元 未持股 2025-05-15

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
James E. Davis Chairman, Chief Executive Officer and President 62 1440.49万美元 11.40 2025-05-15
Mark E. Delaney Senior Vice President and Chief Commercial Officer 57 未披露 未持股 2025-05-15
Karthik Kuppusamy Senior Vice President, Clinical Solutions 55 227.77万美元 1.01 2025-05-15
Patrick Plewman Senior Vice President, Diagnostics Services 58 197.99万美元 未持股 2025-05-15
Sam A. Samad Executive Vice President and Chief Financial Officer 55 406.85万美元 1.51 2025-05-15
Catherine T. Doherty Executive Vice President, Regional Businesses 62 328.61万美元 6.49 2025-05-15
Michael E. Prevoznik Senior Vice President and General Counsel 63 242.86万美元 3.86 2025-05-15

董事简历

中英对照 |  中文 |  英文
James E. Davis

James E. Davis, 2014年2月以来,他一直担任高级副总裁,负责营运。他负责公司诊断信息服务业务和诊断产品业务的运营。他于2013年4月加入奎斯特诊断公司(Quest Diagnostics),担任高级副总裁,负责诊断的解决方案,以及医疗IT、保险服务、临床试验、诊断产品和雇主解决方案业务。从2012年3月到2013年4月,他担任InSightec公司(医疗设备公司, 根据磁共振成像系统设计和开发超声消融设备)的首席董事 ,然后担任首席执行官。之前,他担任通用电气医疗公司多个高级职位,包括通用电气的副总裁和总经理负责磁共振成像业务(从2007年到2012年)。加入通用电气医疗集团之前,他曾担任通用电气航空集团的领导职位,并为麦肯锡咨询公司客户提供发展战略和业务改进计划。


James E. Davis,became Chairman of the Board on April 1, 2023 and Chief Executive Officer and President of the Company on November 1, 2022, having served as CEO-Elect since February 3, 2022. Mr. Davis joined Quest Diagnostics in April 2013 as Senior Vice President, Diagnostics Solutions.Mr. Davis was given positions of increasing responsibility and was named Executive Vice President, General Diagnostics in January 2017.Prior to joining Quest Diagnostics, Mr. Davis served as Lead Director, and then as Chief Executive Officer, of InSightec, Inc., a medical device company that designs and develops ultrasound ablation devices that are guided by magnetic resonance imaging systems. Previously, he held a number of senior positions in General Electric's healthcare business, held leadership positions in General Electric's aviation business and led the development of strategic and operational improvement initiatives for clients of McKinsey & Company, Inc.
James E. Davis, 2014年2月以来,他一直担任高级副总裁,负责营运。他负责公司诊断信息服务业务和诊断产品业务的运营。他于2013年4月加入奎斯特诊断公司(Quest Diagnostics),担任高级副总裁,负责诊断的解决方案,以及医疗IT、保险服务、临床试验、诊断产品和雇主解决方案业务。从2012年3月到2013年4月,他担任InSightec公司(医疗设备公司, 根据磁共振成像系统设计和开发超声消融设备)的首席董事 ,然后担任首席执行官。之前,他担任通用电气医疗公司多个高级职位,包括通用电气的副总裁和总经理负责磁共振成像业务(从2007年到2012年)。加入通用电气医疗集团之前,他曾担任通用电气航空集团的领导职位,并为麦肯锡咨询公司客户提供发展战略和业务改进计划。
James E. Davis,became Chairman of the Board on April 1, 2023 and Chief Executive Officer and President of the Company on November 1, 2022, having served as CEO-Elect since February 3, 2022. Mr. Davis joined Quest Diagnostics in April 2013 as Senior Vice President, Diagnostics Solutions.Mr. Davis was given positions of increasing responsibility and was named Executive Vice President, General Diagnostics in January 2017.Prior to joining Quest Diagnostics, Mr. Davis served as Lead Director, and then as Chief Executive Officer, of InSightec, Inc., a medical device company that designs and develops ultrasound ablation devices that are guided by magnetic resonance imaging systems. Previously, he held a number of senior positions in General Electric's healthcare business, held leadership positions in General Electric's aviation business and led the development of strategic and operational improvement initiatives for clients of McKinsey & Company, Inc.
Wright L. Lassiter III

Wright L. Lassiter III是亨利·福特医疗系统(Henry Ford Health System)的总裁兼首席执行官,该系统位于密歇根州,由六家医院,一项医疗计划以及一系列门诊,零售和相关医疗服务组成。 Lassiter先生于2014年12月加入亨利·福特健康系统,担任总裁,并于2016年出任首席执行官。在加入亨利·福特健康系统之前,他于2005年至2014年担任加利福尼亚州奥克兰Alameda保健系统的首席执行官。目前担任芝加哥联邦储备银行董事局副主席,主持其治理和提名委员会,并担任其审计委员会成员。他还是亨利·福特医疗系统和几个非营利组织的董事会成员,包括底特律投资局,勒莫因学院,莫敦博物馆,底特律市中心合伙企业和底特律地区商会。 Lassiter先生在美国医疗保健系统方面拥有广泛的执行经验,包括治理,战略规划,市场扩展,并购,绩效改善和公司扭亏为盈。


Wright L. Lassiter III,became Chief Executive Officer of CommonSpirit Health, one of the country's largest and most diverse health care organizations, with a network of 140 hospitals and more than 1,500 care sites across 21 states. Prior to joining CommonSpirit Health, he was President and Chief Executive Officer of Henry Ford Health System in Detroit, Michigan from December 2014 to 2022. Prior to that, he was Chief Executive Officer of Alameda Health System in Oakland, California from 2005 to 2014. Mr. Lassiter currently serves on the board of Fortive Corporation and is the Chair of the American Hospital Association. Previously he served on the boards of DT Midstream, Inc. from 2021 to 2023 and Henry Ford Health System and as Vice Chair for the Federal Reserve Bank of Chicago.
Wright L. Lassiter III是亨利·福特医疗系统(Henry Ford Health System)的总裁兼首席执行官,该系统位于密歇根州,由六家医院,一项医疗计划以及一系列门诊,零售和相关医疗服务组成。 Lassiter先生于2014年12月加入亨利·福特健康系统,担任总裁,并于2016年出任首席执行官。在加入亨利·福特健康系统之前,他于2005年至2014年担任加利福尼亚州奥克兰Alameda保健系统的首席执行官。目前担任芝加哥联邦储备银行董事局副主席,主持其治理和提名委员会,并担任其审计委员会成员。他还是亨利·福特医疗系统和几个非营利组织的董事会成员,包括底特律投资局,勒莫因学院,莫敦博物馆,底特律市中心合伙企业和底特律地区商会。 Lassiter先生在美国医疗保健系统方面拥有广泛的执行经验,包括治理,战略规划,市场扩展,并购,绩效改善和公司扭亏为盈。
Wright L. Lassiter III,became Chief Executive Officer of CommonSpirit Health, one of the country's largest and most diverse health care organizations, with a network of 140 hospitals and more than 1,500 care sites across 21 states. Prior to joining CommonSpirit Health, he was President and Chief Executive Officer of Henry Ford Health System in Detroit, Michigan from December 2014 to 2022. Prior to that, he was Chief Executive Officer of Alameda Health System in Oakland, California from 2005 to 2014. Mr. Lassiter currently serves on the board of Fortive Corporation and is the Chair of the American Hospital Association. Previously he served on the boards of DT Midstream, Inc. from 2021 to 2023 and Henry Ford Health System and as Vice Chair for the Federal Reserve Bank of Chicago.
Luiz A. Diaz, Jr.

Luiz A. Diaz, Jr.,自2016年12月起担任Memorial Sloan Kettering Cancer Center实体肿瘤学部门主管。此前,他是约翰霍普金斯大学医学院的教员和医生。他创立了几家生物技术公司,包括Epitope, Inostics, PapGene (Thrive)和Personal Genome Diagnostics, Inc.。Diaz博士的早期工作为Quest Diagnostics提供了第一个明确的证据,将循环肿瘤DNA作为筛选、监测和检测隐匿性疾病的癌症生物标志物。他在错配修复缺陷肿瘤患者中发现了免疫疗法与癌症遗传学之间的治疗联系,这导致了美国食品药品监督管理局(FDA)首次批准了对这种遗传病变的肿瘤进行肿瘤诊断,并于2022年发表了第一项癌症研究,结果100%完全缓解率。Diaz博士从2017年起担任Jounce Therapeutics, Inc.的董事会成员,直到该公司于2023年被收购。他获得了许多奖项和荣誉。Diaz博士于2023年当选为美国国家医学院院士,并于2021年被拜登总统任命为美国国立卫生研究院国家癌症咨询委员会成员。


Luiz A. Diaz, Jr.,has been the head of the division of solid tumor oncology at the Memorial Sloan Kettering Cancer Center since December 2016. Previously, he was a faculty member and physician at the Johns Hopkins University School of Medicine. He has founded several biotechnology companies, including Epitope, Inostics, PapGene (Thrive) and Personal Genome Diagnostics, Inc. Dr. Diaz's early work provided the first definitive evidence for Quest Diagnostics Incorporated ing circulating tumor DNA as cancer biomarker for screening, monitoring, and detection of occult disease. He discovered the therapeutic link between immunotherapy and cancer genetics in patients with mismatch repair deficient tumors, which led to the first tumor agnostic FDA approval for tumors with this genetic lesion and the first cancer study, published in 2022, that resulted in a 100% complete remission rate. Dr. Diaz served on the board of Jounce Therapeutics, Inc. from 2017 until it was acquired in 2023. He is the recipient of numerous awards and honors. Dr. Diaz was elected to the National Academy of Medicine in 2023 and in 2021 he was appointed by President Biden to the National Cancer Advisory Board of the National Institutes of Health.
Luiz A. Diaz, Jr.,自2016年12月起担任Memorial Sloan Kettering Cancer Center实体肿瘤学部门主管。此前,他是约翰霍普金斯大学医学院的教员和医生。他创立了几家生物技术公司,包括Epitope, Inostics, PapGene (Thrive)和Personal Genome Diagnostics, Inc.。Diaz博士的早期工作为Quest Diagnostics提供了第一个明确的证据,将循环肿瘤DNA作为筛选、监测和检测隐匿性疾病的癌症生物标志物。他在错配修复缺陷肿瘤患者中发现了免疫疗法与癌症遗传学之间的治疗联系,这导致了美国食品药品监督管理局(FDA)首次批准了对这种遗传病变的肿瘤进行肿瘤诊断,并于2022年发表了第一项癌症研究,结果100%完全缓解率。Diaz博士从2017年起担任Jounce Therapeutics, Inc.的董事会成员,直到该公司于2023年被收购。他获得了许多奖项和荣誉。Diaz博士于2023年当选为美国国家医学院院士,并于2021年被拜登总统任命为美国国立卫生研究院国家癌症咨询委员会成员。
Luiz A. Diaz, Jr.,has been the head of the division of solid tumor oncology at the Memorial Sloan Kettering Cancer Center since December 2016. Previously, he was a faculty member and physician at the Johns Hopkins University School of Medicine. He has founded several biotechnology companies, including Epitope, Inostics, PapGene (Thrive) and Personal Genome Diagnostics, Inc. Dr. Diaz's early work provided the first definitive evidence for Quest Diagnostics Incorporated ing circulating tumor DNA as cancer biomarker for screening, monitoring, and detection of occult disease. He discovered the therapeutic link between immunotherapy and cancer genetics in patients with mismatch repair deficient tumors, which led to the first tumor agnostic FDA approval for tumors with this genetic lesion and the first cancer study, published in 2022, that resulted in a 100% complete remission rate. Dr. Diaz served on the board of Jounce Therapeutics, Inc. from 2017 until it was acquired in 2023. He is the recipient of numerous awards and honors. Dr. Diaz was elected to the National Academy of Medicine in 2023 and in 2021 he was appointed by President Biden to the National Cancer Advisory Board of the National Institutes of Health.
Gary M. Pfeiffer

Gary M. Pfeiffer ,他于2006年退任杜邦公司(E.I. DuPont de Nemours & Co.) 的高级副总裁兼首席财务官。他于1974年加入杜邦,并负责杜邦及其子公司的金融和国际业务。从2009年1月至6月,他担任特拉华州的财政部秘书。从2005年到2012年,他担任英特奈普网络服务公司的董事,以及塔尔伯特公司的董事。他是特拉华州健康中心的董事会的非执行主席,以及Green tech Capital Advisors公司的咨询委员会成员。2004年12月以来,他一直担任奎斯特诊断公司(Quest Diagnostics)的董事。


Gary M. Pfeiffer,retired in 2006 as the Senior Vice President and Chief Financial Officer of E.I. du Pont de Nemours and Company. He joined DuPont in 1974, where he held positions of increasing responsibility in finance and international operations, as well as in various DuPont divisions. Mr. Pfeiffer served as Secretary of Finance for the state of Delaware from January through June 2009. Mr. Pfeiffer served as a director of Internap Corporation from 2007 to 2020, TerraVia Holdings, Inc. from 2014 to 2017 and Talbots, Inc. from 2005 to 2012. He served as the non-executive Chair of the Board of Directors of Christiana Care Health System, a regional hospital system located in Delaware, from 2012 to 2016.
Gary M. Pfeiffer ,他于2006年退任杜邦公司(E.I. DuPont de Nemours & Co.) 的高级副总裁兼首席财务官。他于1974年加入杜邦,并负责杜邦及其子公司的金融和国际业务。从2009年1月至6月,他担任特拉华州的财政部秘书。从2005年到2012年,他担任英特奈普网络服务公司的董事,以及塔尔伯特公司的董事。他是特拉华州健康中心的董事会的非执行主席,以及Green tech Capital Advisors公司的咨询委员会成员。2004年12月以来,他一直担任奎斯特诊断公司(Quest Diagnostics)的董事。
Gary M. Pfeiffer,retired in 2006 as the Senior Vice President and Chief Financial Officer of E.I. du Pont de Nemours and Company. He joined DuPont in 1974, where he held positions of increasing responsibility in finance and international operations, as well as in various DuPont divisions. Mr. Pfeiffer served as Secretary of Finance for the state of Delaware from January through June 2009. Mr. Pfeiffer served as a director of Internap Corporation from 2007 to 2020, TerraVia Holdings, Inc. from 2014 to 2017 and Talbots, Inc. from 2005 to 2012. He served as the non-executive Chair of the Board of Directors of Christiana Care Health System, a regional hospital system located in Delaware, from 2012 to 2016.
Timothy M. Ring

Timothy M. Ring,他是Quest Diagnostics Incorporated首席独立董事。他于2017年退休,担任C. R. Bard, Inc.的董事长兼首席执行官,自2003年以来一直担任该职位。Ring先生是Becton, Dickinson And Company的董事,2003年至2017年担任C. R. Bard, Inc.的董事,2005年至2009年担任CIT Group Inc.的董事。他是TeamFund, Inc.的联合创始人,TeamFund, Inc.是一家影响力基金和非营利组织,专注于向Sub-Saharan Africa and India提供医疗技术。


Timothy M. Ring,is Lead Independent Director. He retired in 2017 as Chairman and Chief Executive Officer of C. R. Bard, Inc., positions in which he had served since 2003. Mr. Ring is a director of Becton, Dickinson and Company, and was director of C. R. Bard, Inc. from 2003 to 2017 and of CIT Group Inc. from 2005 to 2009. He is a co-founder of TeamFund, Inc., an impact fund and non-profit focused on delivering medical technology to Sub-Saharan Africa and India.
Timothy M. Ring,他是Quest Diagnostics Incorporated首席独立董事。他于2017年退休,担任C. R. Bard, Inc.的董事长兼首席执行官,自2003年以来一直担任该职位。Ring先生是Becton, Dickinson And Company的董事,2003年至2017年担任C. R. Bard, Inc.的董事,2005年至2009年担任CIT Group Inc.的董事。他是TeamFund, Inc.的联合创始人,TeamFund, Inc.是一家影响力基金和非营利组织,专注于向Sub-Saharan Africa and India提供医疗技术。
Timothy M. Ring,is Lead Independent Director. He retired in 2017 as Chairman and Chief Executive Officer of C. R. Bard, Inc., positions in which he had served since 2003. Mr. Ring is a director of Becton, Dickinson and Company, and was director of C. R. Bard, Inc. from 2003 to 2017 and of CIT Group Inc. from 2005 to 2009. He is a co-founder of TeamFund, Inc., an impact fund and non-profit focused on delivering medical technology to Sub-Saharan Africa and India.
Denise M. Morrison

Denise M. Morrison,是咨询公司Denise Morrison & Associates, LLC的创始人。她于2018年退休,担任金宝汤公司的总裁兼首席执行官。她于2003年加入Campbell,担任越来越重要的职位。在加入Campbell之前,她从2001年到2003年在卡夫食品公司担任执行管理职务。她是MetLife, Inc.和Visa, Inc.的董事,并曾担任Campbell Soup Company的董事(2010年至2018年)和The Goodyear Tire & Rubber Company的董事(2005年至2010年)。她是波士顿学院、商业委员会和Just Capital咨询委员会的董事会成员。Morrison女士曾担任Tufts Friedman School of Nutrition Science and Policy的顾问委员会成员;新泽西重启和恢复委员会;特朗普总统的制造业就业计划;以及奥巴马总统的出口委员会。


Denise M. Morrison,is the founder of Denise Morrison & Associates, LLC, a consulting firm. She retired in 2018 as the President and Chief Executive Officer of Campbell Soup Company. Ms. Morrison joined Campbell in 2003, where she held positions of increasing responsibility. Prior to joining Campbell, she held executive management positions at Kraft Foods, Inc. from 2001 to 2003. Ms. Morrison is a director of MetLife, Inc. and Visa, Inc. and served as a director of Campbell Soup Company from 2010 to 2018 and a director of The Goodyear Tire & Rubber Company from 2005 to 2010. She is a member of the Board of Trustees for Boston College, Enterprise Executive Sponsorship Council for Bank of America and the Advisory Council for Just Capital. Ms. Morrison previously served on the Advisory Board for Tufts Friedman School of Nutrition Science and Policy; the New Jersey Restart and Recovery Commission; President Trump's Manufacturing Jobs Initiative; and President Obama's Export Council.
Denise M. Morrison,是咨询公司Denise Morrison & Associates, LLC的创始人。她于2018年退休,担任金宝汤公司的总裁兼首席执行官。她于2003年加入Campbell,担任越来越重要的职位。在加入Campbell之前,她从2001年到2003年在卡夫食品公司担任执行管理职务。她是MetLife, Inc.和Visa, Inc.的董事,并曾担任Campbell Soup Company的董事(2010年至2018年)和The Goodyear Tire & Rubber Company的董事(2005年至2010年)。她是波士顿学院、商业委员会和Just Capital咨询委员会的董事会成员。Morrison女士曾担任Tufts Friedman School of Nutrition Science and Policy的顾问委员会成员;新泽西重启和恢复委员会;特朗普总统的制造业就业计划;以及奥巴马总统的出口委员会。
Denise M. Morrison,is the founder of Denise Morrison & Associates, LLC, a consulting firm. She retired in 2018 as the President and Chief Executive Officer of Campbell Soup Company. Ms. Morrison joined Campbell in 2003, where she held positions of increasing responsibility. Prior to joining Campbell, she held executive management positions at Kraft Foods, Inc. from 2001 to 2003. Ms. Morrison is a director of MetLife, Inc. and Visa, Inc. and served as a director of Campbell Soup Company from 2010 to 2018 and a director of The Goodyear Tire & Rubber Company from 2005 to 2010. She is a member of the Board of Trustees for Boston College, Enterprise Executive Sponsorship Council for Bank of America and the Advisory Council for Just Capital. Ms. Morrison previously served on the Advisory Board for Tufts Friedman School of Nutrition Science and Policy; the New Jersey Restart and Recovery Commission; President Trump's Manufacturing Jobs Initiative; and President Obama's Export Council.
Robert B. Carter

Robert B. Carter,他担任联邦快递信息服务公司的执行副总裁和联邦快递公司(一家运输、电子贸易和商业服务提供商)的首席信息官。2000年至2007年,他担任联邦快递公司的执行副总裁兼首席信息官。5年之内,他还担任Saks公司的董事长,虽然他目前不担任那个职务。2007年,他被选为First Horizon公司的董事长。他在纽约证券交易所上市标准中有独立的地位。他在信息技术领域拥有丰富的经验,并目前担任联邦快递公司的CIO,具有作为一家上市公司总裁的经验。他在Saks人力资源及薪酬和企业管治委员会的服务,增强了他对上市公司的治理和行政人员的薪酬的认识。他还担任一家非营利组织的董事会成员。


Robert B. Carter,retired as Executive Vice President and Chief Information Officer at FedEx Corporation in 2024, where he worked for over 30 years and was responsible for setting the technology direction of the FedEx applications, infrastructure and networks that provide support for FedEx product offerings.Mr. Carter serves on the board of directors of New York Life and previously served on the boards of First Horizon Corporation, Pilot Corporation and Saks, Inc. He also serves on the Board of Trustees for the University of Memphis. Mr. Carter earned a bachelor's degree in computer and information science from the University of Florida, and a master's degree from the University of South Florida.
Robert B. Carter,他担任联邦快递信息服务公司的执行副总裁和联邦快递公司(一家运输、电子贸易和商业服务提供商)的首席信息官。2000年至2007年,他担任联邦快递公司的执行副总裁兼首席信息官。5年之内,他还担任Saks公司的董事长,虽然他目前不担任那个职务。2007年,他被选为First Horizon公司的董事长。他在纽约证券交易所上市标准中有独立的地位。他在信息技术领域拥有丰富的经验,并目前担任联邦快递公司的CIO,具有作为一家上市公司总裁的经验。他在Saks人力资源及薪酬和企业管治委员会的服务,增强了他对上市公司的治理和行政人员的薪酬的认识。他还担任一家非营利组织的董事会成员。
Robert B. Carter,retired as Executive Vice President and Chief Information Officer at FedEx Corporation in 2024, where he worked for over 30 years and was responsible for setting the technology direction of the FedEx applications, infrastructure and networks that provide support for FedEx product offerings.Mr. Carter serves on the board of directors of New York Life and previously served on the boards of First Horizon Corporation, Pilot Corporation and Saks, Inc. He also serves on the Board of Trustees for the University of Memphis. Mr. Carter earned a bachelor's degree in computer and information science from the University of Florida, and a master's degree from the University of South Florida.
Vicky B. Gregg

Vicky B. Gregg,她是Guidon Partners LLC的联合创始人/合伙人。她于2012年退休,担任Blue Cross Blue Shield of Tennessee的首席执行官。在2003年成为首席执行官之前,她曾担任许多其他领导职务,包括总裁和首席运营官。在此之前,她曾在Humana Health Plans担任过一系列高级职位。她曾担任美国国立卫生研究院系统互操作性委员会的成员。她目前担任Acadia Healthcare Company, Inc., Erlanger Health System和查塔努加电力董事会的董事会成员,以及几家私人公司的董事会成员,包括MyEyeDr。此前,她曾在多个董事会任职,包括2013年至2017年担任上市公司TeamHealth Holdings, Inc.和2011年至2015年担任First Horizon Corporation。她还曾担任美国健康保险计划主席,BlueCross BlueShield Association成员,National Institute for Healthcare Management董事会主席,以及Healthcare Leadership Council成员。


Vicky B. Gregg,is a cofounder/partner of Guidon Partners LLC. She retired as Chief Executive Officer of Blue Cross Blue Shield of Tennessee in 2012. Prior to becoming Chief Executive Officer in 2003, Ms. Gregg served in a number of other leadership roles, including President and Chief Operating Officer. Before that, she held a series of senior roles at Humana Health Plans. Ms. Gregg served as a member of the U.S. National Institutes of Health Commission on Systemic Interoperability. She currently serves on the boards of Acadia Healthcare Company, Inc., Erlanger Health System and the Electric Power Board of Chattanooga, as well as the boards of several private companies, including MyEyeDr. Previously, Ms. Gregg served on several boards, including TeamHealth Holdings, Inc., then a public company, from 2013 to 2017 and First Horizon Corporation from 2011 to 2015. She has also served as Chair of America's Health Insurance Plans, as a member of the BlueCross BlueShield Association, as Chair of the Board of the National Institute for Healthcare Management, and as a member of the Healthcare Leadership Council.
Vicky B. Gregg,她是Guidon Partners LLC的联合创始人/合伙人。她于2012年退休,担任Blue Cross Blue Shield of Tennessee的首席执行官。在2003年成为首席执行官之前,她曾担任许多其他领导职务,包括总裁和首席运营官。在此之前,她曾在Humana Health Plans担任过一系列高级职位。她曾担任美国国立卫生研究院系统互操作性委员会的成员。她目前担任Acadia Healthcare Company, Inc., Erlanger Health System和查塔努加电力董事会的董事会成员,以及几家私人公司的董事会成员,包括MyEyeDr。此前,她曾在多个董事会任职,包括2013年至2017年担任上市公司TeamHealth Holdings, Inc.和2011年至2015年担任First Horizon Corporation。她还曾担任美国健康保险计划主席,BlueCross BlueShield Association成员,National Institute for Healthcare Management董事会主席,以及Healthcare Leadership Council成员。
Vicky B. Gregg,is a cofounder/partner of Guidon Partners LLC. She retired as Chief Executive Officer of Blue Cross Blue Shield of Tennessee in 2012. Prior to becoming Chief Executive Officer in 2003, Ms. Gregg served in a number of other leadership roles, including President and Chief Operating Officer. Before that, she held a series of senior roles at Humana Health Plans. Ms. Gregg served as a member of the U.S. National Institutes of Health Commission on Systemic Interoperability. She currently serves on the boards of Acadia Healthcare Company, Inc., Erlanger Health System and the Electric Power Board of Chattanooga, as well as the boards of several private companies, including MyEyeDr. Previously, Ms. Gregg served on several boards, including TeamHealth Holdings, Inc., then a public company, from 2013 to 2017 and First Horizon Corporation from 2011 to 2015. She has also served as Chair of America's Health Insurance Plans, as a member of the BlueCross BlueShield Association, as Chair of the Board of the National Institute for Healthcare Management, and as a member of the Healthcare Leadership Council.
Timothy L. Main

Timothy L. Main,自2013年1月,他担任董事长。他还在Quest Diagnostics公司担任董事。Quest Diagnostics公司致力于提供诊断信息服务。自2000年至2013年3月1日,他担任Jabil公司的首席执行官,并自1999年担任董事。他于1987年进入Jabil公司并担任生产管理经理,于1987年晋升为运营经理,于1989年晋升为项目经理,于1991年担任副总裁,负责业务开发事务,于1996年担任高级副总裁,负责业务开发事务,并于1999年晋升为总裁。在加盟Jabil公司前,他在底特律国家银行(National Bank of Detroit)的国际部担任商业贷款总监。他在密歇根州立大学(Michigan State University)获得学士学位,并在美国雷鸟全球管理学院(American Graduate School of International Management Thunderbird)获得国际管理学硕士学位。


Timothy L. Main,has been the Non-Executive Chairman of WNS (Holdings) Limited since September 2021. From 2000 until 2013 he was the Chief Executive Officer, and from 2013 until 2021 the non-executive Chairman of the Board, of Jabil, Inc., an electronic product solutions company providing comprehensive electronics design, manufacturing and management services to global electronics and technology companies. As Chief Executive Officer, Mr. Main led Jabil's growth strategy, increasing annual revenues nearly five-fold to reach $17 billion in 2012, and expanding in Asia and other emerging markets.
Timothy L. Main,自2013年1月,他担任董事长。他还在Quest Diagnostics公司担任董事。Quest Diagnostics公司致力于提供诊断信息服务。自2000年至2013年3月1日,他担任Jabil公司的首席执行官,并自1999年担任董事。他于1987年进入Jabil公司并担任生产管理经理,于1987年晋升为运营经理,于1989年晋升为项目经理,于1991年担任副总裁,负责业务开发事务,于1996年担任高级副总裁,负责业务开发事务,并于1999年晋升为总裁。在加盟Jabil公司前,他在底特律国家银行(National Bank of Detroit)的国际部担任商业贷款总监。他在密歇根州立大学(Michigan State University)获得学士学位,并在美国雷鸟全球管理学院(American Graduate School of International Management Thunderbird)获得国际管理学硕士学位。
Timothy L. Main,has been the Non-Executive Chairman of WNS (Holdings) Limited since September 2021. From 2000 until 2013 he was the Chief Executive Officer, and from 2013 until 2021 the non-executive Chairman of the Board, of Jabil, Inc., an electronic product solutions company providing comprehensive electronics design, manufacturing and management services to global electronics and technology companies. As Chief Executive Officer, Mr. Main led Jabil's growth strategy, increasing annual revenues nearly five-fold to reach $17 billion in 2012, and expanding in Asia and other emerging markets.
Tracey C. Doi

Tracey C. Doi,2011年8月起担任董事长。2003年起,她担任Toyota Motor Sales, U.S.A., Inc.(一家汽车公司,为丰田、雷克萨斯和后裔汽车的美国售营销和分销部门)副总裁和首席财务官。Doi女士主要负责公司财务、税务、海关、财政、会计、采购、行政服务。她Toyota Motor Sales审计委员会、风险委员会和福利委员会任职,同时也是几家Toyota Motor Sales替公司的董事长或负责人。她于2000年进入Toyota,担任副总裁和企业控制官,2003年晋升为首席财务官。此前,她在AT&T Wireless(一家无线通信公司)、 L.A.Cellular Telephone Company(一家无线通信公司)和L.A.Gear, Inc.(鞋业公司)担任财务管理职位。1983年,她获得UCLA商业经济学学士学位,是一位未在职的注册会计师。她现在是 Federal Reserve Bank of San Francisco经济顾问委员会成员、the Food Allergy Research & Education (FARE)董事会成员、the Japanese American National Museum理事会成员以及US-Japan Council董事会成员。


Tracey C. Doi,retired as Chief Financial Officer and Group Vice President of Toyota Motor North America, Inc. in 2022, after serving nearly twenty years as Chief Financial Officer. Ms. Doi joined Toyota in 2000 as Vice President, Corporate Controller and her responsibilities continued to expand upon her elevation to Chief Financial Officer in 2003. She currently serves on the board of Pentair plc and as an independent trustee of SunAmerica Series Trust and Season Series Trust. Ms. Doi served on the board of City National Bank, a Royal Bank of Canada Company, from 2016 to 2021, and on the Federal Reserve Bank of San Francisco Economic Advisory Council from 2009 to 2016.
Tracey C. Doi,2011年8月起担任董事长。2003年起,她担任Toyota Motor Sales, U.S.A., Inc.(一家汽车公司,为丰田、雷克萨斯和后裔汽车的美国售营销和分销部门)副总裁和首席财务官。Doi女士主要负责公司财务、税务、海关、财政、会计、采购、行政服务。她Toyota Motor Sales审计委员会、风险委员会和福利委员会任职,同时也是几家Toyota Motor Sales替公司的董事长或负责人。她于2000年进入Toyota,担任副总裁和企业控制官,2003年晋升为首席财务官。此前,她在AT&T Wireless(一家无线通信公司)、 L.A.Cellular Telephone Company(一家无线通信公司)和L.A.Gear, Inc.(鞋业公司)担任财务管理职位。1983年,她获得UCLA商业经济学学士学位,是一位未在职的注册会计师。她现在是 Federal Reserve Bank of San Francisco经济顾问委员会成员、the Food Allergy Research & Education (FARE)董事会成员、the Japanese American National Museum理事会成员以及US-Japan Council董事会成员。
Tracey C. Doi,retired as Chief Financial Officer and Group Vice President of Toyota Motor North America, Inc. in 2022, after serving nearly twenty years as Chief Financial Officer. Ms. Doi joined Toyota in 2000 as Vice President, Corporate Controller and her responsibilities continued to expand upon her elevation to Chief Financial Officer in 2003. She currently serves on the board of Pentair plc and as an independent trustee of SunAmerica Series Trust and Season Series Trust. Ms. Doi served on the board of City National Bank, a Royal Bank of Canada Company, from 2016 to 2021, and on the Federal Reserve Bank of San Francisco Economic Advisory Council from 2009 to 2016.

高管简历

中英对照 |  中文 |  英文
James E. Davis

James E. Davis, 2014年2月以来,他一直担任高级副总裁,负责营运。他负责公司诊断信息服务业务和诊断产品业务的运营。他于2013年4月加入奎斯特诊断公司(Quest Diagnostics),担任高级副总裁,负责诊断的解决方案,以及医疗IT、保险服务、临床试验、诊断产品和雇主解决方案业务。从2012年3月到2013年4月,他担任InSightec公司(医疗设备公司, 根据磁共振成像系统设计和开发超声消融设备)的首席董事 ,然后担任首席执行官。之前,他担任通用电气医疗公司多个高级职位,包括通用电气的副总裁和总经理负责磁共振成像业务(从2007年到2012年)。加入通用电气医疗集团之前,他曾担任通用电气航空集团的领导职位,并为麦肯锡咨询公司客户提供发展战略和业务改进计划。


James E. Davis,became Chairman of the Board on April 1, 2023 and Chief Executive Officer and President of the Company on November 1, 2022, having served as CEO-Elect since February 3, 2022. Mr. Davis joined Quest Diagnostics in April 2013 as Senior Vice President, Diagnostics Solutions.Mr. Davis was given positions of increasing responsbility and was named Executive Vice President, General Diagnostics in January 2017.Prior to joining Quest Diagnostics, Mr. Davis served as Lead Director, and then as Chief Executive Officer, of InSightec, Inc., a medical device company that designs and develops ultrasound ablation devices that are guided by magnetic resonance imaging systems. Previously, he held a number of senior positions in General Electric's healthcare business, held leadership positions in General Electric's aviation business and led the development of strategic and operational improvement initiatives for clients of McKinsey & Company, Inc.
James E. Davis, 2014年2月以来,他一直担任高级副总裁,负责营运。他负责公司诊断信息服务业务和诊断产品业务的运营。他于2013年4月加入奎斯特诊断公司(Quest Diagnostics),担任高级副总裁,负责诊断的解决方案,以及医疗IT、保险服务、临床试验、诊断产品和雇主解决方案业务。从2012年3月到2013年4月,他担任InSightec公司(医疗设备公司, 根据磁共振成像系统设计和开发超声消融设备)的首席董事 ,然后担任首席执行官。之前,他担任通用电气医疗公司多个高级职位,包括通用电气的副总裁和总经理负责磁共振成像业务(从2007年到2012年)。加入通用电气医疗集团之前,他曾担任通用电气航空集团的领导职位,并为麦肯锡咨询公司客户提供发展战略和业务改进计划。
James E. Davis,became Chairman of the Board on April 1, 2023 and Chief Executive Officer and President of the Company on November 1, 2022, having served as CEO-Elect since February 3, 2022. Mr. Davis joined Quest Diagnostics in April 2013 as Senior Vice President, Diagnostics Solutions.Mr. Davis was given positions of increasing responsbility and was named Executive Vice President, General Diagnostics in January 2017.Prior to joining Quest Diagnostics, Mr. Davis served as Lead Director, and then as Chief Executive Officer, of InSightec, Inc., a medical device company that designs and develops ultrasound ablation devices that are guided by magnetic resonance imaging systems. Previously, he held a number of senior positions in General Electric's healthcare business, held leadership positions in General Electric's aviation business and led the development of strategic and operational improvement initiatives for clients of McKinsey & Company, Inc.
Mark E. Delaney

Mark E. Delaney,他于2022年3月加入公司,负责所有销售业务。从2017年到2021年Hill-Rom Holdings Inc.被Baxter Healthcare收购,他曾担任Hill-Rom(医疗保健行业医疗技术和相关服务的制造商和提供商)的销售和营销副总裁;被Baxter收购后,他担任Baxter的副总裁兼总经理,直到他加入Quest Diagnostics。此前,他曾在General Electric的医疗保健业务担任多个高级销售和营销领导职务,最近担任高级副总裁兼区域经理,负责成像、患者监测、信息技术和服务的区域销售。


Mark E. Delaney,is responsible for all sales operations. From 2017 until Hill-Rom Holdings Inc. was acquired by Baxter Healthcare in 2021, Mr. Delaney served as Vice President of Sales and Marketing at Hill-Rom, a manufacturer and provider of medical technologies and related services for the healthcare industry; after the acquisition by Baxter Mr. Delaney became Vice President and General Manager at Baxter until he joined Quest Diagnostics.Previously, Mr. Delaney served in a number of senior sales and marketing leadership roles at General Electric's healthcare business, most recently as Senior Vice President and Zone Manager, where he had regional responsibility for sales of imaging, patient monitoring, IT and services.
Mark E. Delaney,他于2022年3月加入公司,负责所有销售业务。从2017年到2021年Hill-Rom Holdings Inc.被Baxter Healthcare收购,他曾担任Hill-Rom(医疗保健行业医疗技术和相关服务的制造商和提供商)的销售和营销副总裁;被Baxter收购后,他担任Baxter的副总裁兼总经理,直到他加入Quest Diagnostics。此前,他曾在General Electric的医疗保健业务担任多个高级销售和营销领导职务,最近担任高级副总裁兼区域经理,负责成像、患者监测、信息技术和服务的区域销售。
Mark E. Delaney,is responsible for all sales operations. From 2017 until Hill-Rom Holdings Inc. was acquired by Baxter Healthcare in 2021, Mr. Delaney served as Vice President of Sales and Marketing at Hill-Rom, a manufacturer and provider of medical technologies and related services for the healthcare industry; after the acquisition by Baxter Mr. Delaney became Vice President and General Manager at Baxter until he joined Quest Diagnostics.Previously, Mr. Delaney served in a number of senior sales and marketing leadership roles at General Electric's healthcare business, most recently as Senior Vice President and Zone Manager, where he had regional responsibility for sales of imaging, patient monitoring, IT and services.
Karthik Kuppusamy

Karthik Kuppusamy于2022年8月担任现职。他负责公司除肿瘤学以外的临床专营权,以及公司的制药服务、基因组服务、医疗事务、医疗质量和全球市场活动。Kuppusamy先生担任包容性和多样性理事会的联合主席。此前,Kuppusamy先生自2018年起担任北区诊断信息服务业务副总裁兼总经理,并于2014年至2017年担任神经科特许经营和消费者遗传学总经理。他于2014年加入公司,此前任职于通用电气的医疗保健业务,在诊断影像事业部担任产品开发、研发、销售和营销总经理职务。


Karthik Kuppusamy,assumed his current role in August 2022. He is responsible for the following clinical franchises: Cardiovascular, Metabolic, Endocrinology and Wellness, Drug Monitoring and Toxicology, Infectious Disease and Immunology, Neurology, and Women's and Reproductive Health. He is also responsible for the Company's genomic customer services, medical affairs, regulatory, LifeLabs and global markets. Previously, Mr. Kuppusamy was Vice President and General Manager of the Company's Diagnostics Information Services business in its North Region since from 2018 and General Manager of the Neurology Franchise and Consumer Genetics from 2014 to 2017. He joined the Company in 2014 from General Electric's healthcare business where he held general manager roles in product development, research and development, sales and marketing in the Diagnostics Imaging Division.
Karthik Kuppusamy于2022年8月担任现职。他负责公司除肿瘤学以外的临床专营权,以及公司的制药服务、基因组服务、医疗事务、医疗质量和全球市场活动。Kuppusamy先生担任包容性和多样性理事会的联合主席。此前,Kuppusamy先生自2018年起担任北区诊断信息服务业务副总裁兼总经理,并于2014年至2017年担任神经科特许经营和消费者遗传学总经理。他于2014年加入公司,此前任职于通用电气的医疗保健业务,在诊断影像事业部担任产品开发、研发、销售和营销总经理职务。
Karthik Kuppusamy,assumed his current role in August 2022. He is responsible for the following clinical franchises: Cardiovascular, Metabolic, Endocrinology and Wellness, Drug Monitoring and Toxicology, Infectious Disease and Immunology, Neurology, and Women's and Reproductive Health. He is also responsible for the Company's genomic customer services, medical affairs, regulatory, LifeLabs and global markets. Previously, Mr. Kuppusamy was Vice President and General Manager of the Company's Diagnostics Information Services business in its North Region since from 2018 and General Manager of the Neurology Franchise and Consumer Genetics from 2014 to 2017. He joined the Company in 2014 from General Electric's healthcare business where he held general manager roles in product development, research and development, sales and marketing in the Diagnostics Imaging Division.
Patrick Plewman

Patrick Plewman于2022年4月担任现职。他负责一系列数据驱动的分析和服务,包括雇主Population Health、医疗保健分析解决方案、Pack Health、风险评估(ExamOne)和雇主解决方案。自2013年加入Quest Diagnostics Incorporated以来,Plewman先生自2018年起担任西部地区诊断信息服务业务的副总裁兼总经理,此前曾担任心血管、代谢和内分泌专营权总经理、传染病和免疫学专营权总经理以及General Health and Wellness专营权总经理。在加入Quest Diagnostics Incorporated之前,Plewman先生曾担任diaDexus公司的联合创始人、总裁和首席执行官。在此之前,Plewman先生曾在SmithKline Beecham公司担任多个职务,职责日益增加。


Patrick Plewman,assumed his current role in April 2022. He is responsible for a portfolio of data driven analytics and services offerings, including Workforce Health Solutions, Healthcare Analytic Solutions, Pack Health, Risk Assessment (ExamOne), Consumer Initiated Testing and Pharma Services. Since joining the Company in 2013, Mr. Plewman was Vice President and General Manager of the Company's Diagnostic Information Services Business in its West Region since 2018 and previously served as General Manager of the Company's Cardiovascular, Metabolic and Endocrinology Franchise, General Manager of the Company's Infectious Disease and Immunology Franchise and General Manager of the General Health and Wellness Franchise.Mr. Plewman serves as Executive Co-Sponsor of the HealthyQuest Employee Business Network.Prior to joining the Company, Mr. Plewman served as Co-Founder, President and Chief Executive Officer of diaDexus, Inc. Previously, Mr. Plewman held various positions of increasing responsibility at SmithKline Beecham.
Patrick Plewman于2022年4月担任现职。他负责一系列数据驱动的分析和服务,包括雇主Population Health、医疗保健分析解决方案、Pack Health、风险评估(ExamOne)和雇主解决方案。自2013年加入Quest Diagnostics Incorporated以来,Plewman先生自2018年起担任西部地区诊断信息服务业务的副总裁兼总经理,此前曾担任心血管、代谢和内分泌专营权总经理、传染病和免疫学专营权总经理以及General Health and Wellness专营权总经理。在加入Quest Diagnostics Incorporated之前,Plewman先生曾担任diaDexus公司的联合创始人、总裁和首席执行官。在此之前,Plewman先生曾在SmithKline Beecham公司担任多个职务,职责日益增加。
Patrick Plewman,assumed his current role in April 2022. He is responsible for a portfolio of data driven analytics and services offerings, including Workforce Health Solutions, Healthcare Analytic Solutions, Pack Health, Risk Assessment (ExamOne), Consumer Initiated Testing and Pharma Services. Since joining the Company in 2013, Mr. Plewman was Vice President and General Manager of the Company's Diagnostic Information Services Business in its West Region since 2018 and previously served as General Manager of the Company's Cardiovascular, Metabolic and Endocrinology Franchise, General Manager of the Company's Infectious Disease and Immunology Franchise and General Manager of the General Health and Wellness Franchise.Mr. Plewman serves as Executive Co-Sponsor of the HealthyQuest Employee Business Network.Prior to joining the Company, Mr. Plewman served as Co-Founder, President and Chief Executive Officer of diaDexus, Inc. Previously, Mr. Plewman held various positions of increasing responsibility at SmithKline Beecham.
Sam A. Samad

Sam A. Samad,他于2022年7月加入公司担任现任职务。他负责公司的财务、会计、投资者关系、内部审计和库务活动。加入公司之前,他曾担任Illumina, Inc. (DNA测序和基于阵列的技术的全球领导者)的首席财务官,2017年以来。加入Illumina之前,他在Cardinal Health担任多个高级领导职位,包括高级副总裁和财务主管,负责Cardinal Health中国业务的运营和财务责任,此前在Eli Lilly and Company担任国内和国际销售和财务职务。


Sam A. Samad,is responsible for the Company's finance, accounting, investor relations, internal audit and treasury activities. Prior to joining the Company, Mr. Samad served as Chief Financial Officer of Illumina, Inc., a global leader in DNA sequencing and array-based technologies, since 2017. Prior to joining Illumina, Mr. Samad held several senior leadership positions at Cardinal Health, including Senior Vice President and Treasurer, with operational and financial responsibility for Cardinal Health's China business, and before that in sales and finance roles at Eli Lilly and Company, both domestically and internationally.
Sam A. Samad,他于2022年7月加入公司担任现任职务。他负责公司的财务、会计、投资者关系、内部审计和库务活动。加入公司之前,他曾担任Illumina, Inc. (DNA测序和基于阵列的技术的全球领导者)的首席财务官,2017年以来。加入Illumina之前,他在Cardinal Health担任多个高级领导职位,包括高级副总裁和财务主管,负责Cardinal Health中国业务的运营和财务责任,此前在Eli Lilly and Company担任国内和国际销售和财务职务。
Sam A. Samad,is responsible for the Company's finance, accounting, investor relations, internal audit and treasury activities. Prior to joining the Company, Mr. Samad served as Chief Financial Officer of Illumina, Inc., a global leader in DNA sequencing and array-based technologies, since 2017. Prior to joining Illumina, Mr. Samad held several senior leadership positions at Cardinal Health, including Senior Vice President and Treasurer, with operational and financial responsibility for Cardinal Health's China business, and before that in sales and finance roles at Eli Lilly and Company, both domestically and internationally.
Catherine T. Doherty

Catherine T. Doherty,自2022年3月起,Doherty女士负责公司区域诊断信息服务业务的综合管理、商业组织和市场营销工作。她还负责推动卓越运营,包括公司的质量和效率举措。Doherty女士是公司女性领导力员工业务网络的执行发起人。从2020年1月到2023年1月,她负责消费者发起的测试,测试在她的领导下启动。2013年1月至2022年3月,Doherty女士担任高级副总裁兼集团执行官-临床特许经营解决方案和营销。在担任这一职务期间,她负责监督在大健康和保健、心血管、代谢和内分泌学、传染病和免疫学以及处方药监测和毒理学领域的临床特许经营解决方案的开发,以及企业范围的营销、雇主解决方案和风险评估业务。从2020年2月开始,奎斯特诊疗公司运动诊断特许经营。她还于2013年1月至2017年1月负责神经内科和女性健康领域的临床特许经营解决方案,并于2014年2月至2017年1月负责医疗保健 IT业务。在2013年1月之前,Doherty女士自1990年加入公司以来担任过多个职责日益增加的职位,包括医师服务高级副总裁;医院服务副总裁;董事长办公室副总裁;医院业务财务和行政副总裁;传播和投资者关系副总裁;以及首席会计官。在2024年期间,她承担了以AmeriPath为品牌的解剖病理学业务的责任,并保留了除营销之外的所有其他职责。


Catherine T. Doherty,has been responsible for the general management of the Company's regional Diagnostic Information Services business, the commercial organization and marketing. She also is responsible for driving operational excellence, including the Company's quality and efficiency initiatives. Ms. Doherty is the Executive Sponsor of the Company's Women in Leadership Employee Business Network.From January 2020 to January 2023, she was responsible for consumer-initiated testing, which was launched under her leadership. From January 2013 to March 2022, Ms. Doherty was Senior Vice President and Group Executive - Clinical Franchise Solutions and Marketing. In this role, she was responsible for overseeing the development of clinical franchise solutions in the areas of general health and wellness, cardiovascular, metabolic and endocrinology, infectious disease and immunology, and prescription drug monitoring and toxicology, as well as enterprise-wide marketing, the employer solutions and risk assessment businesses, and beginning in February 2020, sports diagnostics franchise. She also was responsible for clinical franchise solutions in the areas of neurology and women's health from January 2013 to January 2017 and for the healthcare IT business from February 2014 to January 2017.Prior to January 2013, Ms. Doherty held a variety of positions of increasing responsibility since joining the Company in 1990, including Senior Vice President, Physician Services; Vice President, Hospital Services; Vice President, Office of the Chairman; Vice President, Finance and Administration for the Hospital business; Vice President, Communications and Investor Relations; and Chief Accounting Officer. During 2024 she assumed responsibility for the anatomic pathology business branded AmeriPath and retained all other responsibilities except marketing.
Catherine T. Doherty,自2022年3月起,Doherty女士负责公司区域诊断信息服务业务的综合管理、商业组织和市场营销工作。她还负责推动卓越运营,包括公司的质量和效率举措。Doherty女士是公司女性领导力员工业务网络的执行发起人。从2020年1月到2023年1月,她负责消费者发起的测试,测试在她的领导下启动。2013年1月至2022年3月,Doherty女士担任高级副总裁兼集团执行官-临床特许经营解决方案和营销。在担任这一职务期间,她负责监督在大健康和保健、心血管、代谢和内分泌学、传染病和免疫学以及处方药监测和毒理学领域的临床特许经营解决方案的开发,以及企业范围的营销、雇主解决方案和风险评估业务。从2020年2月开始,奎斯特诊疗公司运动诊断特许经营。她还于2013年1月至2017年1月负责神经内科和女性健康领域的临床特许经营解决方案,并于2014年2月至2017年1月负责医疗保健 IT业务。在2013年1月之前,Doherty女士自1990年加入公司以来担任过多个职责日益增加的职位,包括医师服务高级副总裁;医院服务副总裁;董事长办公室副总裁;医院业务财务和行政副总裁;传播和投资者关系副总裁;以及首席会计官。在2024年期间,她承担了以AmeriPath为品牌的解剖病理学业务的责任,并保留了除营销之外的所有其他职责。
Catherine T. Doherty,has been responsible for the general management of the Company's regional Diagnostic Information Services business, the commercial organization and marketing. She also is responsible for driving operational excellence, including the Company's quality and efficiency initiatives. Ms. Doherty is the Executive Sponsor of the Company's Women in Leadership Employee Business Network.From January 2020 to January 2023, she was responsible for consumer-initiated testing, which was launched under her leadership. From January 2013 to March 2022, Ms. Doherty was Senior Vice President and Group Executive - Clinical Franchise Solutions and Marketing. In this role, she was responsible for overseeing the development of clinical franchise solutions in the areas of general health and wellness, cardiovascular, metabolic and endocrinology, infectious disease and immunology, and prescription drug monitoring and toxicology, as well as enterprise-wide marketing, the employer solutions and risk assessment businesses, and beginning in February 2020, sports diagnostics franchise. She also was responsible for clinical franchise solutions in the areas of neurology and women's health from January 2013 to January 2017 and for the healthcare IT business from February 2014 to January 2017.Prior to January 2013, Ms. Doherty held a variety of positions of increasing responsibility since joining the Company in 1990, including Senior Vice President, Physician Services; Vice President, Hospital Services; Vice President, Office of the Chairman; Vice President, Finance and Administration for the Hospital business; Vice President, Communications and Investor Relations; and Chief Accounting Officer. During 2024 she assumed responsibility for the anatomic pathology business branded AmeriPath and retained all other responsibilities except marketing.
Michael E. Prevoznik

Michael E. Prevoznik,他是高级副总裁兼法律总顾问。他在1999年8月加入了公司,并担任副总裁兼总法律顾问。2003年,他负责政府事务。从1999年到2009年4月,他也负责公司的合规管理部门。2011年4月以来,除了担任总顾问,他担任管理职位,负责该公司在美国之外的诊断信息服务。此外,从2011年4月到2013年1月,他负责管理公司的临床试验业务。在加入公司之前,他担任史克必成( SmithKline Beecham )组织内部合规管理职位,相应责任也越来越大,最近担任合规副总裁,负责协调全球所有史克必成的合规活动。


Michael E. Prevoznik,as Vice President and General Counsel in August 1999. In 2003, he assumed responsibility for governmental affairs. Mr. Prevoznik also is the Vice Chair of the Quest Foundation.From 1999 until April 2009, Mr. Prevoznik also had responsibility for the Company's Compliance Department. In addition, from April 2011 to January 2017, he had management responsibility for the Company's diagnostic information services activities outside the United States, and from April 2011 to January 2013, he had management responsibility for the Company's clinical trials business.Prior to joining the Company, Mr. Prevoznik served in positions of increasing responsibility within the compliance organization at SmithKline Beecham, most recently as Vice President, Compliance, with responsibility for coordinating all SmithKline Beecham compliance activities worldwide.
Michael E. Prevoznik,他是高级副总裁兼法律总顾问。他在1999年8月加入了公司,并担任副总裁兼总法律顾问。2003年,他负责政府事务。从1999年到2009年4月,他也负责公司的合规管理部门。2011年4月以来,除了担任总顾问,他担任管理职位,负责该公司在美国之外的诊断信息服务。此外,从2011年4月到2013年1月,他负责管理公司的临床试验业务。在加入公司之前,他担任史克必成( SmithKline Beecham )组织内部合规管理职位,相应责任也越来越大,最近担任合规副总裁,负责协调全球所有史克必成的合规活动。
Michael E. Prevoznik,as Vice President and General Counsel in August 1999. In 2003, he assumed responsibility for governmental affairs. Mr. Prevoznik also is the Vice Chair of the Quest Foundation.From 1999 until April 2009, Mr. Prevoznik also had responsibility for the Company's Compliance Department. In addition, from April 2011 to January 2017, he had management responsibility for the Company's diagnostic information services activities outside the United States, and from April 2011 to January 2013, he had management responsibility for the Company's clinical trials business.Prior to joining the Company, Mr. Prevoznik served in positions of increasing responsibility within the compliance organization at SmithKline Beecham, most recently as Vice President, Compliance, with responsibility for coordinating all SmithKline Beecham compliance activities worldwide.